bit.bio company branding representing the Cambridge-based biotechnology company developing programmable human cell models for drug discovery and life sciences research.
UK biotechnology company bit.bio has secured $25 million in Series D funding from investors including M&G Investments and Jonathan Milner. The investment will support expansion of its human cell models for drug discovery and life sciences research.

bit.bio, a Cambridge, UK-based biotechnology company specialising in human cell programming, has raised $25 million in Series D funding. The round received backing from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam.

Founded in 2016 by Dr Mark Kotter as a spinout from the University of Cambridge, bit.bio develops human cell models for pharmaceutical companies, biotechnology businesses and academic researchers. The company is led by CEO Dr Emma Pepperell.

The company uses its proprietary opti-ox cell programming technology to produce defined human cell types consistently and at scale. Its portfolio includes more than 50 human cell types across central nervous system, cardiac and liver models, supporting disease research, functional genomics, drug discovery and toxicology testing.

The latest funding will support the expansion of bit.bio‘s human cell portfolio, increase product availability and improve access for research organisations worldwide.

According to the company, paid cell vial volumes increased 76% year to date in 2026, while orders rose 34% and active customers increased 40%. The company also reported 63% growth in academic customers during the same period.

The Series D follows a $50 million Series C round announced in January 2026, led by M&G Investments. That earlier investment was intended to support product development, operational expansion and the broader commercial adoption of the company’s human cell technology.

Get the latest startup funding news in your inbox.

We don’t spam! Read our privacy policy for more info.

Share